Confronting The Challenges Of Marketing Cell And Gene Therapies
Executive Summary
The “chronic disease paradigm” presents a real challenge for companies marketing advanced therapies.
You may also be interested in...
EU New Drug Approvals Hit Record High
Chaos wrought by the ongoing coronavirus pandemic. A heavy workload and continuing resource constraints at the European Medicines Agency. Nonetheless, a record number of novel drugs and vaccines were cleared for marketing in the EU last year.
Do Fast Track Regulatory Pathways Mean Quicker Reimbursement For Gene Therapies?
The norms on securing market access are being rewritten for cell and gene therapies.
Bluebird Exits Europe, Casting Clouds Over Gene Therapy Commercial Effort
The company will prioritize US market for gene therapies; FDA also placed eli-cel for CALD on clinical hold following a case of MDS.